Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TKD activated natural killer cells - Alphageneron Pharmaceuticals/multimmune

Next Previous
Drug Profile

TKD activated natural killer cells - Alphageneron Pharmaceuticals/multimmune

Alternative Names: Activated autologous NK cells - multimmune; Enkastim-ev; Enkastim-iv; Heat shock protein 70 peptide activated natural killer cells; HSP70 peptide activated natural killer cells; Hsp70-peptide TKD/IL-2 activated, autologous NK cells; Natural killer cell therapy - multimmune

Latest Information Update: 10 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator multimmune
  • Developer multimmune; Technical University Munich
  • Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 10 Apr 2024 Alphageneron Pharmaceuticals plans a phase I trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) (Alphageneron Pharmaceuticals Pipeline, April 2024)
  • 18 Oct 2021 Alphageneron Pharmaceuticals plans phase II trial in Non-small cell lung cancer (Late-stage disease) in 2022
  • 18 Oct 2021 Alphageneron intends to submit IND application to the US FDA for initiation of global phase II trial in Non-small cell lung cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top